Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion

Autor: L.M. Sádaba-Echarri, Javier Zarranz-Ventura, Angel Salinas-Alamán, Jose M. Caire González-Jauregui, Alfredo García-Layana, Jesús Barrio-Barrio
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Male
Vascular Endothelial Growth Factor A
Visual acuity
genetic structures
Visual Acuity
Angiogenesis Inhibitors
0302 clinical medicine
Antibodies
monoclonal
humanized/administration and dosage
Fluorescein Angiography
Fisher's exact test
Aged
80 and over
Laser Coagulation
medicine.diagnostic_test
General Medicine
Middle Aged
Combined Modality Therapy
Bevacizumab
Treatment Outcome
Intravitreal Injections
Retreatment
symbols
Female
medicine.symptom
Tomography
Optical Coherence
medicine.drug
medicine.medical_specialty
Antibodies
Monoclonal
Humanized
Macular Edema
Retina
Angiogenesis inhibitors/administration and dosage
03 medical and health sciences
symbols.namesake
Optical coherence tomography
Ophthalmology
Retinal Vein Occlusion
medicine
Humans
Symptom onset
Intravitreal bevacizumab
Macular edema
Aged
business.industry
medicine.disease
eye diseases
030221 ophthalmology & optometry
Branch retinal vein occlusion
sense organs
business
030217 neurology & neurosurgery
Zdroj: Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
Popis: To evaluate intravitreal bevacizumab (IVB) combined with grid laser photocoagulation in macular edema (ME) secondary to branch retinal vein occlusion (BRVO). METHODS: Eight eyes (8 patients) with ME associated with BRVO with at least 3 months of evolution since symptom onset were included. All subjects underwent measurement of best-corrected visual acuity (BCVA) and imaging with spectral domain optical coherence tomography (SD-OCT) at baseline and 1, 3, 6, and 12 months. Intravitreal bevacizumab was administered at baseline and macular grid laser photocoagulation 1 month later. During follow-up, additional IVB was administered based on physician discretion if persistent or recurrent intraretinal fluid (cysts) was observed on SD-OCT. The mean BCVA and SD-OCT central subfield thickness (CST) values were determined at each time point. Fisher exact test was performed to assess differences between baseline and post-treatment BCVA and SD-OCT measurements. RESULTS: The mean baseline BCVA was 0.28+/-0.14 (mean+/-SD), and the mean CST was 479+/-137 microm. The mean BCVAs at 1, 3, 6, and 12 months were 0.47+/-0.18 (p=0.031), 0.56+/-0.50 (p=0.031), 0.65+/-0.60 (p=0.008), and 0.66+/-0.65 (p=0.016), respectively. The mean CST values at 1, 3, 6, and 12 months were 295+/-60 microm (p=0.008), 333+/-114 microm (p=0.070), 339+/-80 microm (p=0.008), and 335+/-109 microm (p=0.008). A mean 2.13 injections were administered; the second injection was administered a mean of 2.71 months after baseline. CONCLUSIONS: Combined treatment with IVB and macular grid photocoagulation provided good results and may be considered as an alternative therapy for ME in BRVO. Further studies are needed to assess these preliminary results.
Databáze: OpenAIRE
Externí odkaz: